scholarly journals Massive Pulmonary Embolism after a Short Episode of Physical Restraint in an Adolescent Psychiatric Patient

2019 ◽  
Vol 08 (04) ◽  
pp. 247-250 ◽  
Author(s):  
Alexander Leibold ◽  
Michael Melter ◽  
Christian Doerfler ◽  
Samra Alikadic ◽  
Markus Zimmermann ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Psychiatric Patients ◽  
Physical Restraint ◽  
Massive Pulmonary Embolism ◽  
Additional Risk ◽  
Vein Thrombosis ◽  
Prophylactic Anticoagulation ◽  
Deep Vein ◽  
Major Adverse Events ◽  
Short Episode

AbstractMedical restraints, when used for short periods of time, can pose additional risk for deep vein thrombosis in adolescent psychiatric patients. The problem is often unrecognized, and there is a lack of awareness of this potential risk. However, as associated major adverse events may result in fatal outcomes, an individual patient's risk for deep vein thrombosis should be assessed and prophylactic anticoagulation may be indicated.

Treatment Of Venous Thromboembolism - Case For Thrombolytic Therapy

1981 ◽  
Author(s):  
V V Kakkar
Keyword(s):  
Deep Vein Thrombosis ◽  
Thrombolytic Therapy ◽  
Massive Pulmonary Embolism ◽  
Vein Thrombosis ◽  
Physiological Processes ◽  
Large Numbers ◽  
Complete Lysis ◽  
Thrombus Removal ◽  
Deep Vein

Thrombolytic therapy has a unique advantage in the treatment of patients suffering from thrombotic disease, since it is capable of inducing the dissolution of intravascular fibrin and thus causing the reduction or elimination of thrombi. The rapidity of thrombus removal distinguishes this form of treatment from anticoagulant therapy, in which normal physiological processes are allowed to restore the obstructed circulation. By quickly removing the obstruction, it should be possible to reduce the mortality arising from acute thromboembolic episodes.The results of therapy for deep-vein thrombosis have been fairly uniform. The published studies can be broadly classified into two main groups; in uncontrolled trials, partial or complete lysis of thrombi was obtained in approximately 65-80% of the patients who received streptokinase, while only 10-25% of the patients receiving heparin showed this change.In patients suffering from acute major or massive pulmonary embolism, a number of trials have demonstrated a more rapid resolution of the embolus than would be expected by treatment with heparin alone.The role of lytic therapy in preventing the late sequelae of deep vein thrombosis at present remains uncertian. Studies involving large numbers of patients and longer periods of follow-up are required to determine the extent to which post phlebitic venous insufficiency is reduced by early thrombolytic therapy.

Metabolic Syndrome and the Incidence of Symptomatic Deep Vein Thrombosis Following Total Knee Arthroplasty

2009 ◽  
Vol 36 (10) ◽  
pp. 2298-2301 ◽  
Author(s):  
RAJIV GANDHI ◽  
FAHAD RAZAK ◽  
PEGGY TSO ◽  
J. RODERICK DAVEY ◽  
NIZAR N. MAHOMED
Keyword(s):  
Metabolic Syndrome ◽  
Deep Vein Thrombosis ◽  
Symptomatic Deep Vein Thrombosis ◽  
Joint Registry ◽  
Vein Thrombosis ◽  
Increased Risk ◽  
Total Knee ◽  
Prophylactic Anticoagulation ◽  
Relationship Of ◽  
Deep Vein

Objective.We asked if patients with metabolic syndrome undergoing total knee replacement (TKR) have an increased risk for symptomatic deep vein thrombosis (DVT) at 3 months followup.Methods.We reviewed 1460 patients from our joint registry undergoing primary, unilateral TKR between 1998–2006. Demographic variables of age, sex, comorbidity, and education were retrieved. Metabolic syndrome was defined as body mass index above 30 kg/m2, diabetes, hypertension, and hypercholesterolemia. Logistic regression was used to examine the relationship of metabolic syndrome on the incidence of DVT.Results.The overall incidence of symptomatic DVT was 4.4% (65/1460). Patients with metabolic syndrome had an increased incidence of DVT compared to those without metabolic syndrome (15.5% vs 3.4%). Adjusted analysis showed that the risk of symptomatic DVT in patients with metabolic syndrome was 3.2 times [odds ratio 3.2, 95% CI (1.0,15.4), p = 0.04] the risk in those without metabolic syndrome.Conclusion.Hospital protocols developed for prophylactic anticoagulation following TKR should give special consideration to patients with metabolic syndrome.

scholarly journals Anticoagulation Treatment for Patients with Coronavirus disease 2019 (COVID-19) and its clinical effectiveness in 2020: A meta-analysis study

2021 ◽  
Author(s):  
Jingyi Ge ◽  
Yingmin Ma ◽  
Zhipeng Wu ◽  
Jiawei Jin ◽  
Xiao Sun
Keyword(s):  
Deep Vein Thrombosis ◽  
Lower Risk ◽  
Cochrane Library ◽  
Vein Thrombosis ◽  
Therapeutic Anticoagulation ◽  
Significant Difference ◽  
Current Outbreak ◽  
Prophylactic Anticoagulation ◽  
And Control ◽  
Deep Vein

Abstract Objective To better inform efforts to treat and control the current outbreak with effective anticoagulant treatment strategies for coronavirus disease 2019 (Covid-19) patients. Methods We searched Cochrane Library, Pubmed, EMBASE, MEDLINE, SCIEXPANDED, Web of Science, Google Scholar, CNKI (Chinese Database), WanFang (Chinese Database), CBM (Chinese Database), VIP (Chinese Database) for studies published from November 1st 2019 to October 1, 2020, and we searched references of identified articles. Studies were reviewed for methodological quality. A random-effects model was used to pool results. Heterogeneity was assessed using I2. Publication bias was assessed using funnel plot. Results Fourteen studies involving 7,681 patients were included. We meta-analyzed the bleeding, deep vein thrombosis and pulmonary embolism risk between no anticoagulation and prophylactic anticoagulation, and found no significant difference. The same trend occurred in the comparison between with and without anticoagulation. However, when compared with no anticoagulation, both prophylactic anticoagulation (OR = 0.80, 95%CI: 0.69–0.93) and therapeutic anticoagulation (OR = 0.91, 95%CI: 0.80–1.05) had lower risk of mortality. Furthermore, the risk of overall bleeding among patients with therapeutic anticoagulation was 3.11 times (95% CI: 2.29–4.24) than that of patients with prophylactic anticoagulation, on the contrary, therapeutic anticoagulation had lower risk of deep vein thrombosis than prophylactic anticoagulation (OR = 0.34, 95%CI: 0.19–0.63). Conclusions Among Covid-19 patients, preventive and therapeutic anticoagulation were more beneficial than no anticoagulation for reducing mortality risk. The result will inform healthcare providers and public health policy makers in their efforts to treat and control the current outbreak.

PULMONARY EMBOLISM AFTER SURGICAL RESECTION OF A MENINGIOMA

Vestnik ◽  
2021 ◽  
pp. 118-121
Author(s):  
Е.К. Дюсембеков ◽  
Е.Б. Алгазиев ◽  
А.К. Жанисбаев ◽  
С.М. Анартаев ◽  
И.А. Канлов ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Deep Vein Thrombosis ◽  
Surgical Resection ◽  
Anticoagulant Therapy ◽  
Clinical Case ◽  
Massive Pulmonary Embolism ◽  
Multidisciplinary Teams ◽  
Vein Thrombosis ◽  
Surgical Methods ◽  
Deep Vein

В статье представлен клинический случай успешного лечения острой массивной тромбоэмболии лёгочной артерии у пациента после удаления менингиомы. Известно, что частота тромбозов глубоких вен нижних конечностей (ТГВ) в нейрохирургической практике достаточно высока, и может достигать 25-34%. ТГВ является основной причиной более грозной тромбоэмболии легочной артерии (ТЭЛА), частота которой составляет от 1,5% до 3%. На сегодняшний день медицина располагает несколькими эффективными инструментами лечения пациентов с ТЭЛА: от антикоагулянтной терапии до хирургических методов реперфузии. Благодаря слаженной работе в современных многопрофильных клиниках интервенционных кардиохирургов, реаниматологов и нейрохирургов, обеспечивающих своевременную и высокоспециализированную помощь, становится возможным спасение жизней пациентов даже с такой тяжелой и жизнеугрожающей патологией как острая массивная тромбоэмболия легочных артерий. The article presents a clinical case of successful treatment of acute massive pulmonary embolism in a patient after resection of a meningioma. The incidence of Deep vein thrombosis (DVT) in neurosurgical practice is astonishingly high as it might reach 25-34% in some reports, and represents the first cause for pulmonary embolism (PE), which incidence is thought to be between 1,5% and 3%. Nowadays there are several options for treating patients with pulmonary embolism: from anticoagulant therapy to surgical methods of reperfusion. Effective multidisciplinary teams and coordinated team in our clinics can save the lives of people with pulmonary embolism.

Sign in / Sign up

Export Citation Format

Share Document